Silas Inman

Silas is the senior vice president, content, at MJH Life Sciences. He began his career at MJH in 2011 as a Web Editor on OncLive. From this role, he moved into managing the social media across the organization and then into broader roles across the content department, first taking on management of HCPLive.

Throughout his tenure at MJH, Silas has been accountable for several organic launches of highly successful brands, including Targeted Oncology and NeurologyLive, and for quickly transforming acquisitions into high-functioning business units. Follow him on X @SilasInman, LinkedIn, sinman@mjhlifesciences.com.

Articles

Cabozantinib Improves OS, PFS in Advanced HCC

January 17th 2018

Treatment with cabozantinib improved median overall survival by 2.2 months compared with placebo for patients with previously treated advanced hepatocellular carcinoma.

FDA Approves Arsenic Trioxide for Promyelocytic Leukemia

January 16th 2018

The FDA has approved arsenic trioxide (Trisenox) in combination with the all-trans retinoic acid agent tretinoin for the treatment of adults with newly-diagnosed low-risk acute promyelocytic leukemia with the t(15;17) translocation or PML-RARA gene expression.

FDA Expands Afatinib's Approval for Lung Cancer

January 14th 2018

The FDA has expanded the frontline indication for afatinib to include the treatment of patients with metastatic non–small cell lung cancer whose tumors harbor uncommon EGFR alterations in L861Q, G719X, and/or S768I.

FDA Grants Priority Review to Novel Iobenguane I-131 Agent for Rare Neuroendocrine Tumors

December 29th 2017

The FDA has granted a priority review designation to a novel version of the radiopharmaceutical iobenguane I-131 for patients with malignant or recurrent pheochromocytoma or paraganglioma.

FDA Approval Sought for Ivosidenib in IDH1+ AML

December 26th 2017

A new drug application has been submitted for ivosidenib for patients with relapsed/refractory IDH1-mutant acute myeloid leukemia, according to a statement from Agios Pharmaceuticals, the company developing the targeted therapy.

Rituximab/Lenalidomide Regimen Misses Endpoint in Phase III Follicular Lymphoma Study

December 22nd 2017

The combination of rituximab and lenalidomide followed by maintenance therapy with the same regimen did not improve response nor progression-free survival compared with rituximab and chemotherapy with rituximab maintenance for patients with previously untreated follicular lymphoma.

FDA Approves Stereotactic Radiotherapy System for Breast Cancer

December 22nd 2017

The FDA has approved a new breast-specific stereotactic body radiotherapy device known as GammaPod as a treatment for patients with breast cancer, based on findings from a 17-patient study.

Roche Gains Entrectinib Through Ignyta Merger

December 22nd 2017

Roche has announced plans to acquire the ROS1/TRK inhibitor entrectinib, through an all-cash $1.7 billion-dollar merger with Ignyta.

FDA Approves Adjuvant Pertuzumab Regimen for HER2+ Breast Cancer

December 21st 2017

The FDA has approved pertuzumab in combination with trastuzumab and chemotherapy as an adjuvant treatment for patients with HER2-positive early breast cancer at high risk for recurrence.

FDA Approves Adjuvant Nivolumab for Melanoma

December 21st 2017

The FDA has approved nivolumab as an adjuvant treatment for patients with completely resected melanoma with lymph node involvement or metastatic disease.

Frontline Findings Put Fresh Focus on Immunotherapy in NSCLC

December 20th 2017

Findings from the phase III IMpower150 study have placed renewed focus on the optimal role for immunotherapy in the frontline setting for patients with advanced non

FDA Approves Bosutinib for Newly-Diagnosed Ph+ CML

December 20th 2017

The FDA has approved bosutinib as a first-line treatment for patients with Philadelphia chromosome-positive chronic myeloid leukemia.

FDA Approves Frontline Cabozantinib for Advanced RCC

December 20th 2017

The FDA has approved cabozantinib for previously untreated patients with advanced renal cell carcinoma.

Olaparib/Durvalumab Combo Effective for BRCA-mutant Breast Cancer

December 14th 2017

The combination of olaparib (Lynparza) and durvalumab (Imfinzi) demonstrated a disease control rate of 80% for pretreated patients with germline BRCA-mutated, HER2-negative metastatic breast cancer,

Ivosidenib Shows High Single-Agent Activity for IDH1-mutant AML

December 13th 2017

The IDH1 inhibitor ivosidenib induced a complete response (CR) or CR with partial hematologic recovery for 30.4% of patients with relapsed/refractory IDH1-mutant acute myeloid leukemia.

Daratumumab Plus VMP New Standard of Care for Some Newly Diagnosed Myeloma Patients

December 12th 2017

The addition of daratumumab to bortezomib, melphalan, and prednisone (VMP) reduced the risk of progression or death by 50% compared with VMP alone for transplant-ineligible patients with newly diagnosed multiple myeloma.

Liso-Cel CR Rate Hits 63% for Relapsed/Refractory DLBCL

December 12th 2017

Liso-cel (lisocabtagene maraleucel), formally known as JCAR017, induced an objective response rate of 81% with a complete remission rate of 63% in patients with relapsed/refractory diffuse large B-cell lymphoma.

Acalabrutinib Highly Effective for Refractory MCL

December 11th 2017

Acalabrutinib demonstrated an objective response rate of 81% with a complete response rate of 40% for patients with refractory mantle cell lymphoma.

Axi-Cel Responses Sustained With Longer Follow-Up for NHL

December 10th 2017

Axi-cel (axicabtagene ciloleucel; Yescarta) maintained a complete remission rate of 40% with a median follow-up of 15.4 months for patients with refractory, aggressive non-Hodgkin lymphoma.

BCMA-Directed bb2121 Highly Effective for Myeloma

December 10th 2017

Treatment with the BCMA-directed CAR T-cell therapy bb2121 induced complete remissions for 56% of patients with relapsed/refractory multiple myeloma.